Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

In vitro to in vivo extrapolation of biotransformation rates for assessing bioaccumulation of hydrophobic organic chemicals in mammals.

Lee YS, Lo JC, Otton SV, Moore MM, Kennedy CJ, Gobas FAPC.

Environ Toxicol Chem. 2017 Jul;36(7):1934-1946. doi: 10.1002/etc.3718. Epub 2017 Feb 6.

PMID:
28000964
2.

Chemical activity-based environmental risk analysis of the plasticizer di-ethylhexyl phthalate and its main metabolite mono-ethylhexyl phthalate.

Gobas FAPC, Otton SV, Tupper-Ring LF, Crawford MA, Clark KE, Ikonomou MG.

Environ Toxicol Chem. 2017 Jun;36(6):1483-1492. doi: 10.1002/etc.3689. Epub 2016 Dec 21.

PMID:
27859543
3.

Concentration dependence of biotransformation in fish liver S9: Optimizing substrate concentrations to estimate hepatic clearance for bioaccumulation assessment.

Lo JC, Allard GN, Otton SV, Campbell DA, Gobas FA.

Environ Toxicol Chem. 2015 Dec;34(12):2782-90. doi: 10.1002/etc.3117. Epub 2015 Oct 15.

PMID:
26077187
4.

In vitro biotransformation rates in fish liver S9: effect of dosing techniques.

Lee YS, Lee DH, Delafoulhouze M, Otton SV, Moore MM, Kennedy CJ, Gobas FA.

Environ Toxicol Chem. 2014 Aug;33(8):1885-93. doi: 10.1002/etc.2636. Epub 2014 Jun 20.

PMID:
24832019
5.

Relationship between biodegradation and sorption of phthalate esters and their metabolites in natural sediments.

Kickham P, Otton SV, Moore MM, Ikonomou MG, Gobas FA.

Environ Toxicol Chem. 2012 Aug;31(8):1730-7. doi: 10.1002/etc.1903. Epub 2012 Jul 3.

PMID:
22648531
6.

Measuring in vitro biotransformation rates of super hydrophobic chemicals in rat liver s9 fractions using thin-film sorbent-phase dosing.

Lee YS, Otton SV, Campbell DA, Moore MM, Kennedy CJ, Gobas FA.

Environ Sci Technol. 2012 Jan 3;46(1):410-8. doi: 10.1021/es203338h. Epub 2011 Dec 12.

PMID:
22126411
7.

Assessing exposure of sediment biota to organic contaminants by thin-film solid phase extraction.

Meloche LM, DeBruyn AM, Otton SV, Ikonomou MG, Gobas FA.

Environ Toxicol Chem. 2009 Feb;28(2):247-53. doi: 10.1897/08-081.1.

PMID:
18763874
8.

Biodegradation of mono-alkyl phthalate esters in natural sediments.

Otton SV, Sura S, Blair J, Ikonomou MG, Gobas FA.

Chemosphere. 2008 May;71(11):2011-6. doi: 10.1016/j.chemosphere.2008.01.059. Epub 2008 Mar 10.

PMID:
18331756
9.

Cytochrome P450 2D6 and treatment of codeine dependence.

Romach MK, Otton SV, Somer G, Tyndale RF, Sellers EM.

J Clin Psychopharmacol. 2000 Feb;20(1):43-5.

PMID:
10653207
10.
11.

Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.

Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, Tyndale RF.

Pharmacogenetics. 1998 Aug;8(4):325-33.

PMID:
9731719
12.

Effect of CYP2D1 inhibition on the behavioural effects of d-amphetamine.

Tomkins DM, Otton SV, Joharchi N, Berns T, Wu D, Corrigall WA, Sellers EM.

Behav Pharmacol. 1997 Jun;8(2-3):223-35.

PMID:
9833017
13.

Interactions of amphetamine analogs with human liver CYP2D6.

Wu D, Otton SV, Inaba T, Kalow W, Sellers EM.

Biochem Pharmacol. 1997 Jun 1;53(11):1605-12.

PMID:
9264312
14.

CYP2D6 inhibition in patients treated with sertraline.

Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Sellers EM.

J Clin Psychopharmacol. 1997 Apr;17(2):102-6.

PMID:
10950472
15.

Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.

Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, Sellers EM.

J Pharmacol Exp Ther. 1997 Apr;281(1):103-8.

PMID:
9103485
16.

Simultaneous gas chromatographic determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine.

Cheung S, Nolte H, Otton SV, Tyndale RF, Wu PH, Sellers EM.

J Chromatogr B Biomed Sci Appl. 1997 Mar 7;690(1-2):77-87.

PMID:
9106031
17.

Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats.

Tomkins DM, Otton SV, Joharchi N, Li NY, Balster RF, Tyndale RF, Sellers EM.

J Pharmacol Exp Ther. 1997 Mar;280(3):1374-82.

PMID:
9067326
18.

The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse.

Sellers EM, Otton SV, Tyndale RF.

NIDA Res Monogr. 1997;173:6-26. Review. No abstract available.

PMID:
9260180
19.

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM.

Br J Clin Pharmacol. 1996 Feb;41(2):149-56.

20.

Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat.

Wu D, Otton SV, Kalow W, Sellers EM.

J Pharmacol Exp Ther. 1995 Sep;274(3):1431-7.

PMID:
7562518
21.

Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.

Schadel M, Wu D, Otton SV, Kalow W, Sellers EM.

J Clin Psychopharmacol. 1995 Aug;15(4):263-9.

PMID:
7593709
22.

CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.

Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM.

Clin Pharmacol Ther. 1993 Nov;54(5):463-72.

PMID:
7693389
23.

Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro.

Wu D, Otton SV, Morrow P, Inaba T, Kalow W, Sellers EM.

J Pharmacol Exp Ther. 1993 Aug;266(2):715-9.

PMID:
8355202
24.

Inhibition by fluoxetine of cytochrome P450 2D6 activity.

Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM.

Clin Pharmacol Ther. 1993 Apr;53(4):401-9.

PMID:
8477556
25.

Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.

Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, Sellers EM.

Br J Clin Pharmacol. 1993 Jan;35(1):30-4.

26.

Catalytic and immunologic similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6).

Otton SV, Tyndale RF, Wu D, Inaba T, Kalow W, Sellers EM.

Drug Metab Dispos. 1992 Jan-Feb;20(1):1-5.

PMID:
1346982
27.

Drug metabolism and interactions in abuse liability assessment.

Sellers EM, Otton SV, Busto UE.

Br J Addict. 1991 Dec;86(12):1607-14. Review.

PMID:
1786494
28.

Assessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine type.

Adams M, Lennard MS, Otton SV, Tucker GT, Woods HF.

Biochem Pharmacol. 1991 Jul 25;42(4):947-9. No abstract available.

PMID:
1867648
29.

Characterization of metronidazole metabolism by human liver microsomes.

Loft S, Otton SV, Lennard MS, Tucker GT, Poulsen HE.

Biochem Pharmacol. 1991 Apr 15;41(8):1127-34.

PMID:
2009091
30.
31.

Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.

Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF.

J Pharmacol Exp Ther. 1988 Oct;247(1):242-7.

PMID:
3171974
32.

In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.

Otton SV, Brinn RU, Gram LF.

Drug Metab Dispos. 1988 Jan-Feb;16(1):15-7.

PMID:
2894945
33.

Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.

Brøsen K, Otton SV, Gram LF.

Clin Pharmacol Ther. 1986 Nov;40(5):543-9.

PMID:
3769385
34.

Sparteine oxidation is practically abolished in quinidine-treated patients.

Brinn R, Brøsen K, Gram LF, Haghfelt T, Otton SV.

Br J Clin Pharmacol. 1986 Aug;22(2):194-7.

35.

Sparteine oxidation polymorphism: a family study.

Brøsen K, Otton SV, Gram LF.

Br J Clin Pharmacol. 1986 Jun;21(6):661-7.

36.

A simple borohydride/GC method for measuring sparteine metabolites in man.

Inaba T, Vinks A, Otton SV.

Br J Clin Pharmacol. 1986 May;21(5):473-80.

37.

Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

Brøsen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L.

Eur J Clin Pharmacol. 1986;30(6):679-84.

PMID:
3533565
38.

Sparteine oxidation polymorphism in Denmark.

Brøsen K, Otton SV, Gram LF.

Acta Pharmacol Toxicol (Copenh). 1985 Nov;57(5):357-60.

PMID:
4090995
39.
40.

A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.

Inaba T, Nakano M, Otton SV, Mahon WA, Kalow W.

Can J Physiol Pharmacol. 1984 Jul;62(7):860-2.

PMID:
6498616
41.
42.

Comparative pharmacogenetics of sparteine and debrisoquine.

Inaba T, Vinks A, Otton SV, Kalow W.

Clin Pharmacol Ther. 1983 Mar;33(3):394-9.

PMID:
6825393
43.

Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs.

Otton SV, Inaba T, Kalow W.

Life Sci. 1983 Feb 14;32(7):795-800.

PMID:
6827912
44.

In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.

Otton SV, Inaba T, Mahon WA, Kalow W.

Can J Physiol Pharmacol. 1982 Jan;60(1):102-5.

PMID:
7066751
45.

Sparteine metabolism in Canadian Caucasians.

Vinks A, Inaba T, Otton SV, Kalow W.

Clin Pharmacol Ther. 1982 Jan;31(1):23-9.

PMID:
7053300
46.

Debrisoquine hydroxylation capacity: problems of assessment in two populations.

Inaba T, Otton SV, Kalow W.

Clin Pharmacol Ther. 1981 Feb;29(2):218-23.

PMID:
7460485
47.

Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals.

Kalow W, Otton SV, Kadar D, Endrenyi L, Inaba T.

Can J Physiol Pharmacol. 1980 Sep;58(9):1142-4.

PMID:
7459706
48.

Deficient metabolism of debrisoquine and sparteine.

Inaba T, Otton SV, Kalow W.

Clin Pharmacol Ther. 1980 Apr;27(4):547-9.

PMID:
7357813

Supplemental Content

Loading ...
Support Center